Trade AnaptysBio - ANAB CFD
Add to favourite- Summary
- Historical Data
Spread | 0.28 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 37.57 |
Open | 37.45 |
1-Year Change | 113.88% |
Day's Range | 36.86 - 38.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 37.17 | 0.29 | 0.79% | 36.88 | 38.76 | 36.70 |
Jul 24, 2024 | 36.83 | 1.05 | 2.93% | 35.78 | 37.35 | 35.77 |
Jul 23, 2024 | 36.92 | 1.66 | 4.71% | 35.26 | 37.24 | 34.98 |
Jul 22, 2024 | 35.64 | 1.49 | 4.36% | 34.15 | 35.66 | 33.56 |
Jul 19, 2024 | 33.70 | -3.53 | -9.48% | 37.23 | 37.23 | 33.61 |
Jul 18, 2024 | 34.39 | 0.24 | 0.70% | 34.15 | 36.15 | 33.95 |
Jul 17, 2024 | 34.41 | 1.46 | 4.43% | 32.95 | 34.74 | 32.95 |
Jul 16, 2024 | 34.34 | 1.77 | 5.43% | 32.57 | 34.90 | 32.14 |
Jul 15, 2024 | 32.66 | 2.61 | 8.69% | 30.05 | 32.90 | 28.96 |
Jul 12, 2024 | 29.99 | -0.02 | -0.07% | 30.01 | 31.27 | 29.87 |
Jul 11, 2024 | 30.20 | 3.77 | 14.26% | 26.43 | 30.56 | 26.43 |
Jul 10, 2024 | 27.19 | 1.21 | 4.66% | 25.98 | 27.23 | 25.09 |
Jul 9, 2024 | 25.67 | 0.48 | 1.91% | 25.19 | 25.75 | 24.88 |
Jul 8, 2024 | 25.35 | 0.70 | 2.84% | 24.65 | 25.79 | 24.65 |
Jul 5, 2024 | 24.66 | -0.14 | -0.56% | 24.80 | 25.10 | 24.29 |
Jul 3, 2024 | 24.76 | 0.31 | 1.27% | 24.45 | 25.34 | 24.25 |
Jul 2, 2024 | 23.89 | 0.12 | 0.50% | 23.77 | 24.60 | 23.63 |
Jul 1, 2024 | 24.56 | -0.07 | -0.28% | 24.63 | 25.29 | 24.28 |
Jun 28, 2024 | 24.95 | 0.45 | 1.84% | 24.50 | 25.12 | 24.34 |
Jun 27, 2024 | 24.73 | 0.53 | 2.19% | 24.20 | 24.78 | 23.43 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AnaptysBio Company profile
About AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AnaptysBio Inc revenues decreased 16% to $63.2M. Net loss increased from $19.9M to $57.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 22% to $92.6M (expense), Interest income decrease of 89% to $431K (income).
Industry: | Bio Therapeutic Drugs |
10770 Wateridge Circle, Suite 210
SAN DIEGO
CALIFORNIA 92121
US
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com